The MINDACT trial: the first prospective clinical validation of a genomic tool
about
Breast cancer in the personal genomics eraProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerIdentifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomesProgress in adjuvant chemotherapy for breast cancer: an overviewProspective Validation of a 21-Gene Expression Assay in Breast CancerA thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest.Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancerA fuzzy gene expression-based computational approach improves breast cancer prognosticationMinimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Equivalence of MammaPrint array types in clinical trials and diagnostics.A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancerDesign and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survivalIntra-tumour signalling entropy determines clinical outcome in breast and lung cancer.Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsA three-gene model to robustly identify breast cancer molecular subtypesmiR-30e* is an independent subtype-specific prognostic marker in breast cancerAdoption of gene expression profile testing and association with use of chemotherapy among women with breast cancerAn "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes.Selecting cases for whom additional tests can improve prognostication.MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience.A catalyst for change: the European cancer Patient's Bill of Rights.Risk modeling strategies for pharmacogenetic studies.A guide to stem cell identification: progress and challenges in system-wide predictive testing with complex biomarkers.Biomarkers in the diagnosis of primary and recurrent breast cancer.The classification of invasive carcinoma of the breast.News on the medical treatment of young women with early-stage HER2-negative breast cancer.Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.Molecular and clinicopathological markers of prognosis in breast cancer.Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology.Is there a niche for DNA microarrays in molecular diagnostics?Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.Comparing diagnostic tests: trials in people with discordant test results.Cancer clinical trials in the era of genomic signatures: biomedical innovation, clinical utility, and regulatory-scientific hybrids.The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients.The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
P2860
Q24602679-95AD3B39-EE67-4801-9EBD-1352100257DFQ24632628-09BEA7A3-20BA-43BB-A506-22A792FDD97CQ26778675-B4B044A3-EB84-4A44-8D72-D8D718290A28Q26798078-877F5790-0945-472C-91E5-37D47F24EA64Q29011698-9F336030-C059-4580-BC22-C4888242824FQ30410836-76661A88-59BB-464E-B502-376B04FD3015Q30566197-DB958DD1-9EE1-4071-AB94-21DF72A8B265Q33861620-C2746C62-B199-4949-9366-EB443E38CBD0Q34233815-1722CFA3-7F4A-4261-9654-D6184AB00E58Q34519347-916465C1-50E8-4D66-8FA8-ABAE5AADDE39Q34854883-4F4B9DA1-8BFE-478D-AD93-1432E2294F6DQ35084044-558E2771-BA04-4461-AF88-E1CAAA2BBF21Q35203271-86419F20-57EB-4202-80F0-8FD868FAC1AAQ35740423-AF05F434-AD6E-4E9C-B6B2-FF16A375991FQ35769036-CDCAF23E-4B23-498F-B811-C4A99EF327D0Q35863168-F61768B7-A666-41B9-980B-85763E09A7CFQ36097503-DC3D3354-2B35-41F9-859B-86854FDE5FBEQ36187733-3E94E8DC-158E-4BCE-8A0B-9C0E45513B29Q36443179-0E1AFADD-80B5-4118-A8E4-7DDBF5B75A8EQ36519219-BA517FE7-4FE9-45D4-9FA2-ACA911B0C41EQ37288135-C4BC35A8-045C-481C-BE7D-7AC979035A31Q37644553-C266F58C-5830-4259-AFB7-DD0BD6FF6B3AQ37859373-D892D574-5938-4903-AFE7-DE92BE6EB733Q37929077-925B8F85-DB26-4FF0-81CB-13EDFE955A2DQ38052925-328131F0-A87D-4703-AC59-BEE42F3C767EQ38132239-D9FA49DC-2774-4DAE-A196-A60E13B70694Q38870541-D2917047-427B-4318-9C46-F66DF4128217Q38933874-DA836CA8-AAF8-4020-899C-0BDDADD6E4AFQ39272347-67FED2D7-6C05-447A-85D6-860DBA10AACCQ39399933-DBBA9130-8F3A-43CB-A699-90B34B170034Q39612569-46648FBD-5925-4EB2-B3E1-4CDA37859513Q39955702-F925C66C-ED02-433F-8DE3-806BABF5CBC8Q41135122-3A5704D0-847B-4083-AF92-B08BF985A535Q44102194-F0F5E724-8ABB-4193-AEDD-16F4C6120AA6Q45078570-8135BE32-729A-49A2-90FF-D5A9346B527EQ45771015-C4DB2784-3F47-44AC-B2C6-6206EB6B9C79Q47835415-042F0789-DB52-4977-9591-A13AA3C60888Q49843589-5D79B59B-1165-487E-82E1-E789BB2E8FB1Q53085805-44DDA41E-CB89-4422-A359-0F4F2F83873EQ53254550-8C807A87-35E2-4461-A30F-29F18555E4E1
P2860
The MINDACT trial: the first prospective clinical validation of a genomic tool
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The MINDACT trial: the first prospective clinical validation of a genomic tool
@ast
The MINDACT trial: the first prospective clinical validation of a genomic tool
@en
The MINDACT trial: the first prospective clinical validation of a genomic tool
@nl
type
label
The MINDACT trial: the first prospective clinical validation of a genomic tool
@ast
The MINDACT trial: the first prospective clinical validation of a genomic tool
@en
The MINDACT trial: the first prospective clinical validation of a genomic tool
@nl
prefLabel
The MINDACT trial: the first prospective clinical validation of a genomic tool
@ast
The MINDACT trial: the first prospective clinical validation of a genomic tool
@en
The MINDACT trial: the first prospective clinical validation of a genomic tool
@nl
P2093
P2860
P3181
P1433
P1476
The MINDACT trial: the first prospective clinical validation of a genomic tool
@en
P2093
Emiel Rutgers
Laura Van't Veer
TRANSBIG Consortium
P2860
P304
P3181
P356
10.1016/J.MOLONC.2007.10.004
P407
P577
2007-10-22T00:00:00Z